molecular beacons

Contact Information

You can visit our laboratory, which is located at:


Public Health Research Institute
New Jersey Medical School - Rutgers, The State University of New Jersey
Department of Molecular Genetics, Third floor - West Wing
225 Warren Street
Newark, New Jersey 07103

PHRI is a Center of the New Jersey Medical School at Rutgers, The State University of New Jersey. For more information on our University, please visit

If you need directions to our Institute, you can click this link
and Google Maps will help you.



For inquiries on the molecular beacon licensing program, you can contact

Fred Russell Kramer, Ph.D.
Tel: 1-973-854-3370
Fax: 1-973-854-3371


For inquiries on molecular beacon applications, molecular beacon design,
and molecular beacon synthesis, you can contact

Sanjay Tyagi, Ph.D. Salvatore A.E. Marras, Ph.D.
Tel: 1-973-854-3372 Tel: 1-973-854-3373
Fax: 1-973-854-3374 Fax: 1-973-854-3374


Members of the Department of Molecular Genetics

Fred Russell Kramer
Salvatore A.E. Marras
Sanjay Tyagi
Diana Y. Vargas


  To top of page



Recent Publications from our group

Vargas DY, Marras SAE, Tyagi S, and Kramer FR. (2018) Suppression of Wild-Type Amplification by Selectivity Enhancing Agents in PCR Assays That Utilize SuperSelective Primers for the Detection of Rare Somatic Mutations. The Journal of Molecular Diagnostics, 20, 415-427

Schlachter S, Chan K, Marras SAE, and Parveen N (2017) Detection and differentiation of lyme spirochetes and other tick-borne pathogens from blood using real-time PCR with molecular beacons. Methods in Molecular Biology 1616: 155-170.

Catrina IE, Bayer LV, Yanez G, McLaughlin JM, Malaczek K, Bagaeva E, Marras SAE, and Bratu DP (2016) The temporally controlled expression of Drongo, the fruit fly homolog of AGFG1, is achieved in female germline cells via P-bodies and its localization requires functional Rab11. RNA Biol 13: 1117-1132.

Vargas DY, Kramer FR, Tyagi S, and Marras SAE. (2016) Multiplex real-time PCR assays that measure the abundance of extremely rare mutations associated with cancer. PLoS ONE 11, e0156546.

We describe the use of SuperSelective primers that enable the detection and quantitation of somatic mutations whose presence relates to cancer diagnosis, prognosis, and therapy, in real-time multiplex PCR assays that can potentially analyze rare DNA fragments present in blood samples (liquid biopsies), thereby providing information that can be used to modify therapy for individual patients, prolonging (and improving the quality of) life.

Follow this link to access this article.